The US Food and Drug Administration approved CSPC Pharmaceutical's (HKG:1093) US clinical trials for its JMT108 drug for advanced malignant tumors, according to a Tuesday filing with the Hong Kong bourse.
The product relieves immunosuppression on programmed cell death protein 1 positive tumor infiltrating immune cells, the filing said.
Shares in the drug company fell 4% during Wednesday's morning trading.